Adimab LLC announced three deals in a single day Wednesday by disclosing it will transfer its platform to Takeda Pharmaceuticals Co. Ltd., expand on an earlier multitarget research agreement with Regeneron Pharmaceuticals Inc. and up the ante on an agreement with Novartis AG to optimize antibodies against nine targets.